-
EP2844294
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2844294
| EP2844294 - PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 12.02.2016 Database last updated on 02.11.2024 | Most recent event Tooltip | 12.02.2016 | Application deemed to be withdrawn | published on 16.03.2016 [2016/11] | Applicant(s) | For all designated states Jagotec AG Eptingerstrasse 61 4132 Muttenz / CH | [2015/11] | Inventor(s) | 01 /
GRENIER, Pascal La Clef des Champs 5 rue des Vignes F-68510 Kappelen / FR | 02 /
VERGNAULT, Guy 9 rue des Merles F-68680 Kembes / FR | [2015/11] | Representative(s) | (deleted) | [N/P] |
| Former [2015/11] | Mintz Levin Cohn Ferris Glovsky and Popeo LLP Alder Castle 10 Noble Street London EC2V 7JX / GB | Application number, filing date | 13720409.5 | 03.05.2013 | WO2013EP59307 | Priority number, date | GB20120007886 | 04.05.2012 Original published format: GB 201207886 | [2015/11] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013164473 | Date: | 07.11.2013 | Language: | EN | [2013/45] | Type: | A1 Application with search report | No.: | EP2844294 | Date: | 11.03.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 07.11.2013 takes the place of the publication of the European patent application. | [2015/11] | Search report(s) | International search report - published on: | EP | 07.11.2013 | Classification | IPC: | A61K47/14, A61K47/20, A61K47/22, A61K47/24, A61K47/36, A61K9/14, A61K31/58, A61P35/00 | [2015/11] | CPC: |
A61K31/58 (EP,US);
A61K47/12 (US);
A61K47/20 (US);
A61K47/22 (US);
A61K47/26 (US);
A61K9/145 (EP,US);
A61K9/2018 (EP,US);
A61P13/08 (EP);
A61P35/00 (EP);
A61P43/00 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/11] | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT ABIRATERONACETAT | [2015/11] | English: | PHARMACEUTICAL COMPOSITION COMPRISING ABIRATERONE ACETATE | [2015/11] | French: | COMPOSITION PHARMACEUTIQUE COMPRENANT L'ACÉTATE D'ABIRATÉRONE | [2015/11] | Entry into regional phase | 28.11.2014 | National basic fee paid | 28.11.2014 | Designation fee(s) paid | 28.11.2014 | Examination fee paid | Examination procedure | 28.11.2014 | Examination requested [2015/11] | 03.09.2015 | Application deemed to be withdrawn, date of legal effect [2016/11] | 14.10.2015 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time [2016/11] | 14.10.2015 | Despatch of communication of loss of particular rights: Claims {1} | Fees paid | Renewal fee | 13.05.2015 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2008024484 (COUGAR BIOTECHNOLOGY INC [US], et al) [X] 1-16 * abstract * * paragraphs [0035] , [0077] - [0078] - [0083] *; | [X]WO2012013331 (GP PHARM SA [ES], et al) [X] 1-16 * abstract *; | [Y] - European Medicines Agency, "Assessment Report For Zytiga (abiraterone)", (20110721), URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002321/WC500112860.pdf, (20130531), XP002698002 [Y] 1-16 * In particular parts 2.2.2. and 2.2.3. at pages 9 to 10 * | [Y] - Griffin, Brendan, "Advances in Lipid-based Formulations: Overcoming the Challenge of Low Bioavailability for Poorly Water Soluble Drug Compounds", American Pharmaceutical Review, (20120330), URL: http://www.americanpharmaceuticalreview.com/Featured-Articles/39299-Advances-in-Lipid-based-Formulations-Overcoming-the-Challenge-of-Low-Bioavailability-for-Poorly-Water-Soluble-Drug-Compounds/, (20130531), XP002698003 [Y] 1-16 * the whole document * |